Patterns of use of heparins in ACS

Summary

A systematic study that compares the patterns of use of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in patients with acute coronary syndromes (ACS) has, to date, not been carried out in the “real-world” setting. The aim of this report is to identify patterns of use of UFH and LMWH and to report their correlates and outcomes in a broad spectrum of ACS patients enrolled in the observational Global Registry of Acute Coronary Events (GRACE).

The use of LMWH and UFH was analysed in 13,231 ACS patients according to patient history, concomitant treatment and invasive procedures in US and non-US sites. Frequency of use in hospitals with and without facilities for percutaneous coronary interventions (PCI) was investigated, and outcomes were analysed.

Results show that younger patients (<60 years), those receiving antiplatelet therapies, thrombolytics, beta-blockers, angiotensin-converting enzyme inhibitors, patients admitted to hospitals with PCI facilities, and patients undergoing invasive procedures were more likely to receive UFH, or both UFH and LMWH than LMWH alone (80.1% enoxaparin, 19.9% other LMWH). LMWH was used less often in US than non-US sites. After adjusting for confounding variables, patients receiving LMWH had significantly lower rates of hospital mortality (P=0.009) and major bleeding (P<0.0001). Similar results were observed in patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction or unstable angina.

We can conclude that UFH tends to be used more frequently than LMWH, but hospital outcomes appeared to be better with LMWH after adjusting for covariables.

Keywords

Low-molecular-weight heparin - unfractionated heparin - acute coronary syndromes - outcomes

^† A complete list of investigators and institutions can be found in the Appendix

• References

• 1 Fox KAA, Cokkinos DV, Deckers J. et al. on behalf of the ENACT (European Network for Acute Coronary Treatment) investigators. The ENACT study: a pan-European survey of acute coronary syndromes. Eur Heart J 2001; 21: 1440-9.
• 2 Turpie AGG, Antman EM. Low-molecular-weight heparins in the treatment of acute coronary syndromes. Arch Intern Med 2001; 161: 1484-90.
• 3 Almeda FQ, Snell RJ, Paririllo JE. The contemporary management of acute myocardial infarction. Crit Care Clin 2001; 17: 411-34.
• 4 Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-8.
• 5 Klein W, Buchwald A, Hillis SE. et al. for the FRIC Investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for six weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96: 61-8.
• 6 The FRAX.I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAX.I.S. FRA Xiparine in Ischaemic Syndrome. Eur Heart J 1999; 20: 1553-62.
• 7 Cohen M, Demers C, Gurfinkel EP. et al. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-52.
• 8 Antman EM, McCabe CH, Gurfinkel EP. et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial. Circulation 1999; 100: 1593-601.
• 9 The Assessment of the safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenec-teplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
• 10 Antman EM, Louwerenburg HW, Baars HF. et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction. Results of the ENTIRE-Thrombolysis In Myocardial Infarction (TIMI) 23 Trial. Circulation 2002; 105: r27-r34.
• 11 Ross AM, Molhoek P, Lundergan C. et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin. Second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104: 648-52.
• 12 Simoons M, Krzeminska-Pakula M, Alonso A. et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 2002; 23: 1282.
• 13 The GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: A multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001; 141: 190-9.
• 14 Steg PhG, Goldberg RJ, Gore JM. et al. for the GRACE Investigators. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002; 90: 358-63.
• 15 Eagle KA, Goodman SG, Avezum Á, Budaj A, Sullivan CM, López-Sendón J. for the GRACE Investigators. Practice variation and missed opportunities for reperfusion in ST-segment elevation myocardial infarction – findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002; 359: 373-7.
• 16 Goodman SG, Cohen M, Bigonzi F. et al. for the ESSENCE study group. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease. One-year results of the ESSENCE study. J Am Coll Cardiol 2000; 36: 693-8.
• 17 The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design. J Throm Thrombolysis 2000; 10: 241-6.
• 18 Fox KAA, Goodman SG, Klein W. et al. Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89.
• 19 Wallentin L, Armstrong P, Granger C. et al. for the ASSENT-III PLUS investigators. Assessment of the safety and efficacy of a new thrombolytic regimen in the pre-hospital setting (ASSENT III Plus). Circulation 2002; 106: 2986.
• 20 Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?. J Am Coll Cardiol 2000; 35: 1699-712.
• 21 Young JJ, Kereiakes DJ, Grines CL. for the National Investigators Collaborating on Enoxaparin (NICE) Investigators. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. J Invas Cardiol 2000; 12 (Suppl E) E14-E18.
• 22 Ferguson JJ. Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: The NICE 3 story. J Invas Cardiol 2000; 12 (Suppl E) E10-E13.